Suven Life Sciences Ltd. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Suven Life Sciences Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Suven Life Sciences Ltd. - Product Pipeline Review - 2014', provides an overview of the Suven Life Sciences Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Suven Life Sciences Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Suven Life Sciences Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Suven Life Sciences Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Suven Life Sciences Ltd.'s pipeline products

Reasons to buy

- Evaluate Suven Life Sciences Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Suven Life Sciences Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Suven Life Sciences Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Suven Life Sciences Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Suven Life Sciences Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Suven Life Sciences Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Suven Life Sciences Ltd. Snapshot 6
Suven Life Sciences Ltd. Overview 6
Key Information 6
Key Facts 6
Suven Life Sciences Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Suven Life Sciences Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Suven Life Sciences Ltd. - Pipeline Products Glance 13
Suven Life Sciences Ltd. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Suven Life Sciences Ltd. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 16
Suven Life Sciences Ltd. - Drug Profiles 17
SUVN-502 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule Targeting 5-HT4 Receptor for Alzheimer Disease 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecule Targeting 5-HT4 Receptor for Cognitive Disorders 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecule to Agonize Cannabinoid Receptor-2 for Pain 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SUVN-1004028 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SUVN-501 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
SUVN-504 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SUVN-507 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SUVN-901 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SUVN-90121 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SUVN-91052 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SUVN-911 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SUVN-91121 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SUVN-976 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SUVN-D-1108121 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SUVND-1003019 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SUVND-1104010 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SUVNF-90101 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SUVNF-91201 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SUVNG-1010034 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SUVNG-1031 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tetrahydrocarbazole Derivatives 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug Targeting Histamine-3 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Drug Targeting Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 for Neuro Degenerative Diseases 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drug Targeting Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 for Obesity And Metabolic Disorders 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drug Targeting Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 for Pain 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Suven Life Sciences Ltd. - Pipeline Analysis 43
Suven Life Sciences Ltd. - Pipeline Products by Target 43
Suven Life Sciences Ltd. - Pipeline Products by Route of Administration 44
Suven Life Sciences Ltd. - Pipeline Products by Molecule Type 45
Suven Life Sciences Ltd. - Pipeline Products by Mechanism of Action 46
Suven Life Sciences Ltd. - Recent Pipeline Updates 48
Suven Life Sciences Ltd. - Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Suven Life Sciences Ltd., Key Information 6
Suven Life Sciences Ltd., Key Facts 6
Suven Life Sciences Ltd. - Pipeline by Indication, 2014 8
Suven Life Sciences Ltd. - Pipeline by Stage of Development, 2014 11
Suven Life Sciences Ltd. - Monotherapy Products in Pipeline, 2014 12
Suven Life Sciences Ltd. - Phase I, 2014 13
Suven Life Sciences Ltd. - Preclinical, 2014 14
Suven Life Sciences Ltd. - Discovery, 2014 16
Suven Life Sciences Ltd. - Pipeline by Target, 2014 43
Suven Life Sciences Ltd. - Pipeline by Route of Administration, 2014 44
Suven Life Sciences Ltd. - Pipeline by Molecule Type, 2014 45
Suven Life Sciences Ltd. - Pipeline Products by Mechanism of Action, 2014 47
Suven Life Sciences Ltd. - Recent Pipeline Updates, 2014 48
Suven Life Sciences Ltd., Other Locations 52